Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

23.45 +0.32 (+1.36%)
Streaming Delayed Price Updated: 10:19 AM EDT, Sep 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
18 19 Next >
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – APLS
From The Rosen Law Firm, P.A.
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday's trading, 46 companies set new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Where Apellis Pharmaceuticals Stands With Analysts
 
Via Benzinga
The Latest Analyst Ratings for Apellis Pharmaceuticals
 
Via Benzinga
Apellis Pharmaceuticals Inc. (NASDAQ: APLS) is a Stock Spotlight on 5/25
Via Investor Brand Network
Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) gained 90% to $0.3560 after the company issued strategic update and announced restructuring. 
Via Benzinga
Why Are Apellis Pharmaceuticals Shares More Down 20% Today?
Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading lower amid safety concerns regarding the company's newly launched Syfovre (pegcetacoplan injection) for geographic atrophy (GA) secondary... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Needham Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To Know
 
Via Benzinga
Top-Notch Biotech Apellis Soars After New Drug Obliterates Sales Views
The company easily beat sales calls on the back of Syfovre, a geography atrophy drug. 
Via Investor's Business Daily
The Latest Analyst Ratings for Apellis Pharmaceuticals
 
Via Benzinga
Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers ProMIS Neurosciences, Inc. (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived... 
Via Benzinga
Ford Motor, AT&T, Frontier Communications And Other Big Stocks Moving Lower On Monday
U.S. stocks traded higher, with the Dow Jones gaining over 50 points on Monday. Here are some big stocks recording losses in today’s session. Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) shares... 
Via Benzinga
Apellis Pharma Crashes After Safety Report Undercuts Its Newest Eye Drug
Now, investors are questioning the future for Apellis' Syfovre, an eye-disease treatment. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why BYND Cannasoft Enterprises Shares Are Trading Lower By 40%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday! 
Via InvestorPlace
Apellis Announces Seven Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
Apellis Pharma Flunks On Primary, Secondary Endpoints In Amyotrophic Lateral Sclerosis Study
 
Via Benzinga
Why Shares of Annexon Are Plummeting Thursday
Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock. 
Via The Motley Fool
Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Why These 3 Nasdaq Stocks Buckled Today
The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today. 
Via The Motley Fool
Are Small Caps a Harbinger of Market Declines?
The iShares Russell 2000 ETF outperformed the S&P 500 last week, but that may be short-lived. Small-cap momentum is often a bellwether for broad-market action. 
Via MarketBeat
Topics ETFs Stocks
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
Apellis Pharma's Newly Approved Drug Exceeds Sales Projections, Bullish Analyst Raises Expectations
Apellis Pharmaceuticals Inc (NASDAQ: APLS) reported Q1 revenues of $44.8 million, surpassing the consensus of $26.10 million and  
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.